Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor ...

Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...

We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

23andMe filed for bankruptcy protection in March ... plus an additional 50% on a second for a full immersive day of AI! Hear from AI pioneers from Google DeepMind, OpenAI, Anthropic, and more ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced today that it will acquire 23andMe for a purchase price of $256 million. 23andMe had filed for bankruptcy protection in March this year, while ...

Regeneron Pharmaceuticals said it will buy genetic testing company 23andMe out of bankruptcy for $256 million.